Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer(PEOC)
- VernacularTitle:上皮性卵巢癌ATP肿瘤体外药物敏感性试验的临床应用可行性
- Author:
Guolan GAO
;
Qingping QI
;
Xuesen ZOU
;
Wenxue CHEN
- Publication Type:Journal Article
- Keywords:
ATP-tumor chemosensitivity assay;
primary epithelial ovarian cancer;
anticancer drug
- From:
China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Because of the heterogeneity of cancers,different patients with the same kind of cancer have different sensitivity for cytotoxic drugs.Newly developed ATP chemosensitivity assays(ATPTCA) offer the opportunity for individualized therapy and have shown promising results compared to standard regimens.We explored the feasibility of the ATP-Tumor Chemosensitivity Assay(ATP-TCA) applied in the treatment of ovarian cancer with chemotherapy,and evaluate the in vitro sensitivity of fresh specimens of ovarian cancer to five cytotoxic drugs.Methods:ATP-TCA was used to detect the sensitivity rate of 24 fresh specimens of ovarian cancer to five cytotoxic drugs as follows: paclitaxel(TAX),gemcitabine(GEM),doxorubicin(ADM),topotecan(TPT),cisplatin(DDP).Results:23 of 24 specimens((95.83%)) can be evaluated by ATP-TCA,the sensitive rates of ATP-TCA was 91.30% for TAX,86.96% for GEM,65.22% for ADM,47.83% for TPT and 21.74% for DDP,respectively.Conclusions:ATP-TCA was a sensitive、reliable and standardized method for the evaluation of tumor chemosensitivity,it ts worthwhile to investigate further for the application screening anticancer agents in chemotherapy of ovarian cancer.
